Research progress on lncRNAs as members of ceRNA network in melanoma

Abstract

Hong Anlan, Cao Meng, Wang Yan, Fang Fang. Research progress on lncRNAs as members of ceRNA network in melanoma[J]. Journal of International Oncology, 2022, 49(1): 61-64.

References37

[1]	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(1):7-30. DOI: 10.3322/caac.21590. doi:10.3322/caac.21590
[2]	Riefolo M, Porcellini E, Dika E, et al. Interplay between small and long non-coding RNAs in cutaneous melanoma: a complex jigsaw puzzle with missing pieces[J]. Mol Oncol, 2019, 13(1):74-98. DOI: 10.1002/1878-0261.12412. doi:10.1002/1878-0261.12412pmid:30499222
[3]	Schmitt AM, Chang HY. Long noncoding RNAs in cancer pathways[J]. Cancer Cell, 2016, 29(4):452-463. DOI: 10.1016/j.ccell.2016.03.010. doi:S1535-6108(16)30092-7pmid:27070700
[4]	Salmena L, Poliseno L, Tay Y, et al. A ceRNA hypojournal: the rosetta stone of a hidden RNA language?[J]. Cell, 2011, 146(3):353-358. DOI: 10.1016/j.cell.2011.07.014. doi:10.1016/j.cell.2011.07.014
[5]	Yu X, Zheng H, Tse G, et al. Long non-coding RNAs in melanoma[J]. Cell Prolif, 2018, 51(4):e12457. DOI: 10.1111/cpr.12457. doi:10.1111/cpr.12457
[6]	Luan W, Li R, Liu L, et al. Long non-coding RNA HOTAIR acts as a competing endogenous RNA to promote malignant melanoma progression by sponging miR-152-3p[J]. Oncotarget, 2017, 8(49):85401-85414. DOI: 10.18632/oncotarget.19910. doi:10.18632/oncotarget.19910
[7]	Cantile M, Scognamiglio G, Marra L, et al. HOTAIR role in melanoma progression and its identification in the blood of patients with advanced disease[J]. J Cell Physiol, 2017, 232(12):3422-3432. DOI: 10.1002/jcp.25789. doi:10.1002/jcp.25789pmid:28067428
[8]	Wang P, Hu L, Fu G, et al. LncRNA MALAT1 promotes the proli-feration, migration, and invasion of melanoma cells by downregulating miR-23a[J]. Cancer Manag Res, 2020, 12:6553-6562. DOI: 10.2147/CMAR.S249348. doi:10.2147/CMAR.S249348pmid:32801893
[9]	Li F, Li X, Qiao L, et al. MALAT1 regulates miR-34a expression in melanoma cells[J]. Cell Death Dis, 2019, 10(6):389. DOI: 10.1038/s41419-019-1620-3. doi:10.1038/s41419-019-1620-3
[10]	Sun Y, Cheng H, Wang G, et al. Deregulation of miR-183 promotes melanoma development via lncRNA MALAT1 regulation and ITGB1 signal activation[J]. Oncotarget, 2017, 8(2):3509-3518. DOI: 10.18632/oncotarget.13862. doi:10.18632/oncotarget.13862
[11]	Han C, Tang F, Chen J, et al. Knockdown of lncRNA-UCA1 inhi-bits the proliferation and migration of melanoma cells through modulating the miR-28-5p/HOXB3 axis[J]. Exp Ther Med, 2019, 17(5):4294-4302. DOI: 10.3892/etm.2019.7421. doi:10.3892/etm.2019.7421
[12]	Chen X, Gao J, Yu Y, et al. Long non-coding RNA UCA1 targets miR-185-5p and regulates cell mobility by affecting epithelial-mesenchymal transition in melanoma via Wnt/β-catenin signaling pathway[J]. Gene, 2018, 676:298-305. DOI: 10.1016/j.gene.2018.08.065. doi:10.1016/j.gene.2018.08.065
[13]	Wei Y, Sun Q, Zhao L, et al. LncRNA UCA1-miR-507-FOXM1 axis is involved in cell proliferation, invasion and G₀/G₁cell cycle arrest in melanoma[J]. Med Oncol, 2016, 33(8):88. DOI: 10.1007/s12032-016-0804-2. doi:10.1007/s12032-016-0804-2
[14]	Chen X, Gao G, Liu S, et al. Long noncoding RNA PVT1 as a novel diagnostic biomarker and therapeutic target for melanoma[J]. Biomed Res Int, 2017, 2017:7038579. DOI: 10.1155/2017/7038579. doi:10.1155/2017/7038579
[15]	Wang BJ, Ding HW, Ma GA. Long noncoding RNA PVT1 promotes melanoma progression via endogenous sponging miR-26b[J]. Oncol Res, 2018, 26(5):675-681. DOI: 10.3727/096504017X-14920318811730. doi:10.3727/096504017X-14920318811730
[16]	Zhou H, Sun L, Wan F. Molecular mechanisms of TUG1 in the proliferation, apoptosis, migration and invasion of cancer cells[J]. Oncol Lett, 2019, 18(5):4393-4402. DOI: 10.3892/ol.2019.10848. doi:10.3892/ol.2019.10848pmid:31611948
[17]	Liu W, Feng Q, Liao W, et al. TUG1 promotes the expression of IFITM3 in hepatocellular carcinoma by competitively binding to miR-29a[J]. J Cancer, 2021, 12:6905-6920. DOI: 10.7150/jca.57477. doi:10.7150/jca.57477
[18]	Yuan JB, Gu L, Chen L, et al. Annexin A8 regulated by lncRNA-TUG1/miR-140-3p axis promotes bladder cancer progression and metastasis[J]. Mol Ther Oncolytics, 2021, 22:36-51. DOI: 10.1016/j.omto.2021.04.008. doi:10.1016/j.omto.2021.04.008
[19]	Liu Q, Zhang W, Luo L, et al. Long noncoding RNA TUG1 regulates the progression of colorectal cancer through miR-542-3p/TRIB2 axis and Wnt/β-catenin pathway[J]. Diagn Pathol, 2021, 16(1):47. DOI: 10.1186/s13000-021-01101-7. doi:10.1186/s13000-021-01101-7
[20]	Wang Y, Liu G, Ren L, et al. Long non-coding RNA TUG1 recruits miR-29c-3p from its target gene RGS1 to promote proliferation and metastasis of melanoma cells[J]. Int J Oncol, 2019, 54(4):1317-1326. DOI: 10.3892/ijo.2019.4699. doi:10.3892/ijo.2019.4699
[21]	Long J, Menggen Q, Wuren Q, et al. Long noncoding RNA taurine-upregulated gene1 (TUG1) promotes tumor growth and metastasis through TUG1/miR-129-5p/astrocyte-elevated gene-1 (AEG-1) axis in malignant melanoma[J]. Med Sci Monit, 2018, 24:1547-1559. DOI: 10.12659/msm.906616. doi:10.12659/msm.906616
[22]	Fan J, Kang X, Zhao L, et al. Long noncoding RNA CCAT1 functions as a competing endogenous RNA to upregulate ITGA9 by sponging miR-296-3p in melanoma[J]. Cancer Manag Res, 2020, 12:4699-4714. DOI: 10.2147/CMAR.S252635. doi:10.2147/CMAR.S252635
[23]	Lv L, Jia JQ, Chen J. The lncRNA CCAT1 upregulates proliferation and invasion in melanoma cells via suppressing miR-33a[J]. Oncol Res, 2018, 26(2):201-208. DOI: 10.3727/096504017X1-4920318811749. doi:10.3727/096504017X1-4920318811749
[24]	Pan B, Lin X, Zhang L, et al. Long noncoding RNA X-inactive specific transcript promotes malignant melanoma progression and oxaliplatin resistance[J]. Melanoma Res, 2019, 29(3):254-262. DOI: 10.1097/CMR.0000000000000560. doi:10.1097/CMR.0000000000000560
[25]	Tian K, Sun D, Chen M, et al. Long noncoding RNA X-inactive specific transcript facilitates cellular functions in melanoma via miR-139-5p/ROCK1 pathway[J]. Onco Targets Ther, 2020, 13:1277-1287. DOI: 10.2147/OTT.S225661. doi:10.2147/OTT.S225661
[26]	Ma MH, An JX, Zhang C, et al. ZEB1-AS1 initiates a miRNA-mediated ceRNA network to facilitate gastric cancer progression[J]. Cancer Cell Int, 2019, 19:27. DOI: 10.1186/s12935-019-0742-0. doi:10.1186/s12935-019-0742-0
[27]	Xia W, Jie W. ZEB1-AS1/miR-133a-3p/LPAR3/EGFR axis promotes the progression of thyroid cancer by regulating PI3K/AKT/mTOR pathway[J]. Cancer Cell Int, 2020, 20:94. DOI: 10.1186/s12935-020-1098-1. doi:10.1186/s12935-020-1098-1pmid:32231464
[28]	Wang Q, Zhang R, Liu D. Long non-coding RNA ZEB1-AS1 indicates poor prognosis and promotes melanoma progression through targeting miR-1224-5p[J]. Exp Ther Med, 2019, 17(1):857-862. DOI: 10.3892/etm.2018.7005. doi:10.3892/etm.2018.7005
[29]	Siena ÁDD, Plaça JR, Araújo LF, et al. Whole transcriptome analysis reveals correlation of long noncoding RNA ZEB1-AS1 with invasive profile in melanoma[J]. Sci Rep, 2019, 9(1):11350. DOI: 10.1038/s41598-019-47363-6. doi:10.1038/s41598-019-47363-6
[30]	Moradi MT, Fallahi H, Rahimi Z. Interaction of long noncoding RNA MEG3 with miRNAs: a reciprocal regulation[J]. J Cell Biochem, 2019, 120(3):3339-3352. DOI: 10.1002/jcb.27604. doi:10.1002/jcb.27604
[31]	Al-Rugeebah A, Alanazi M, Parine NP. MEG3: an oncogenic long non-coding RNA in different cancers[J]. Pathol Oncol Res, 2019, 25(3):859-874. DOI: 10.1007/s12253-019-00614-3. doi:10.1007/s12253-019-00614-3pmid:30793226
[32]	Long J, Pi X. lncRNA-MEG3 suppresses the proliferation and invasion of melanoma by regulating CYLD expression mediated by sponging miR-499-5p[J]. Biomed Res Int, 2018, 2018:2086564. DOI: 10.1155/2018/2086564. doi:10.1155/2018/2086564
[33]	Wu L, Zhu L, Li Y, et al. LncRNA MEG3 promotes melanoma growth, metastasis and formation through modulating miR-21/E-cadherin axis[J]. Cancer Cell Int, 2020, 20:12. DOI: 10.1186/s12935-019-1087-4. doi:10.1186/s12935-019-1087-4
[34]	Kolenda T, Rutkowski P, Michalak M, et al. Plasma lncRNA expression profile as a prognostic tool in BRAF-mutant metastatic melanoma patients treated with BRAF inhibitor[J]. Oncotarget, 2019, 10(39):3879-3893. DOI: 10.18632/oncotarget.26989. doi:10.18632/oncotarget.26989pmid:31231466
[35]	Yu X, Zheng H, Tse G, et al. CASC2: an emerging tumour-suppressing long noncoding RNA in human cancers and melanoma[J]. Cell Prolif, 2018, 51(6):e12506. DOI: 10.1111/cpr.12506. doi:10.1111/cpr.12506
[36]	Wang Z, Wang X, Zhou H, et al. Long non-coding RNA CASC2 inhibits tumorigenesis via the miR-181a/PLXNC1 axis in melanoma[J]. Acta Biochim Biophys Sin (Shanghai), 2018, 50(3):263-272. DOI: 10.1093/abbs/gmx148. doi:10.1093/abbs/gmx148
[37]	Zhang Y, Qian W, Feng F, et al. Upregulated lncRNA CASC2 may inhibit malignant melanoma development through regulating miR-18a-5p/RUNX1[J]. Oncol Res, 2019, 27(3):371-377. DOI: 10.3727/096504018X15178740729367. doi:10.3727/096504018X15178740729367

Research progress on lncRNAs as members of ceRNA network in melanoma

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References37

Related Articles15

Recommended Articles

Metrics

Comments

[1]	Gong Yan, Chen Honglei.Research progress on the mechanism of microRNA regulation of cisplatin resistance in ovarian cancer[J]. Journal of International Oncology, 2024, 51(3): 186-190.
[2]	Wu Minhang, Sun Wenzheng, Yu Qingzhuo, Guo Rong, Ye Hui, Du Ying, Qiu Jin, An Huazhang, Cao Lili.RNF43 inhibits PD-L1 expressionviaβ-catenin in melanoma cells and promotes CD8⁺T cell-mediated anti-tumor immune reaction[J]. Journal of International Oncology, 2023, 50(7): 407-412.
[3]	Quan Zhenhao, Xu Feipeng, Huang Zhe, Huang Xianjin, Chen Rihong, Sun Kaiyu, Hu Xu, Lin Lin.lncRNA FTX silencing inhibits gastric cancer cell proliferation through the miR-22-3p/NLRP3 inflammasome pathway[J]. Journal of International Oncology, 2023, 50(4): 202-207.
[4]	Zhou Renbang, Zhang Zhongchuan, Xu Zhiyuan, Zhu Xunbing.MiR-219a-5p inhibits the proliferation, invasion and migration of osteosarcoma U2OS cells by negatively regulating HMGA2[J]. Journal of International Oncology, 2022, 49(4): 193-198.
[5]	Jin Jiahui, Chen Cunhai, Ma Xuezhen.Effects of radiation-associated miRNA in radiotherapy for breast cancer[J]. Journal of International Oncology, 2022, 49(12): 735-738.
[6]	Jing Wenjun, Zhao Wenwen, Feng Qingqing, Zhao Wenfei, Zhao Lili, Zhang Xue, Wei Hongmei.Molecular basis and clinical prospect of the miR-34 family for the treatment of gastric cancer[J]. Journal of International Oncology, 2022, 49(11): 681-686.
[7]	Luo Liyun, Lai Canhui, Liang Renpei, Yang Aiwu, Lin Zhimin.Correlation between the expressions of miR-524-5p and SOX9 in advanced gastric cancer and their influences on chemotherapy efficacy and prognosis[J]. Journal of International Oncology, 2022, 49(1): 45-50.
[8]	Liu Pei, Pu Jiaze, Huang Wen, Wang Fei.Expression differences of miR-200c, miR-19a and miR-155 in gefitinib sensitive and drug resistant NSCLC patients and their effects on prognosis[J]. Journal of International Oncology, 2021, 48(7): 409-414.
[9]	Wang Yang, Liu Qian, Long Hui, Wu Qingming.Research status of fecal detection for colorectal cancer markers[J]. Journal of International Oncology, 2021, 48(7): 441-444.
[10]	Cheng Yiming, Li Gang, Wang Zhenming, Lyu Qianwen, Li Shirong.Value of serum miR-196a-5p and miR-105-5p in differential diagnosis of benign and malignant pulmonary nodules[J]. Journal of International Oncology, 2021, 48(5): 282-286.
[11]	Deng Bo'er, Kong Weimin.Epigenetic research progress of endometrial cancer[J]. Journal of International Oncology, 2021, 48(3): 184-188.
[12]	Li Bingliang, Yang Ya, Huang Yingli, Si Wen, Li Xingwei, Zhang Yuanmin, Bian Jichao, Chen Yu.Effects of miR-20a-5p targeting KDM6B on the proliferation, migration and invasion of osteosarcoma cells[J]. Journal of International Oncology, 2021, 48(2): 65-73.
[13]	He Miao, Fan Kui, Cao Fang.Epigenetics and drug resistance in lung cancer[J]. Journal of International Oncology, 2021, 48(10): 622-626.
[14]	Zhou Jiamin, Ye Lisha, Wang Guohua.Roles of microRNA in the regulation of tumor-associated macrophage polarization during the remodeling of breast cancer immune microenvironment[J]. Journal of International Oncology, 2020, 47(7): 428-430.
[15]	Yang Lifen, Song Wei, Xu Dawei, Wu Jun, Gao Ran.Mechanisms of miR-103a-3p/CHI3L1 in proliferation and vascular mimicry of ovarian cancer cells[J]. Journal of International Oncology, 2020, 47(6): 333-339.